Clinical Trial: Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).
Study Status: Completed
Recruit Status: RECRUITING
Condition: Head and Neck Squamous Cell Carcinoma
Study Type: INTERVENTIONAL
Official Title: Neoadjuvant Pembrolizumab and IO102-103 Prior to Curative-intent Surgical Care for Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Brief Summary:
This research is being done to see if it is safe to give investigational combination of study drugs (Pembrolizumab and IO102-103) before surgery to people with surgically resectable (removable) newly diagnosed or recurrent metastatic SCCHN.This will be done by watching participants closely for possible side effects from Pembrolizumab and IO102-103.In addition, participants will be monitored for any delays to their surgery due to the study drugs.
Read more